Assignee
argenx BV
BE·20 granted patents·37 pending applications·29 citations·filing 2017–2025
Top patents by PatentIndex Score
57 records- 0192US11505585B2FcRn antagonists and methods of useargenx BV·Filed 2017·Granted Nov 22, 2022·7 cites·10 claims
- 0290US12344678B2FcRn/HSA binding molecules and methods of useargenx BV·Filed 2024·Granted Jul 1, 2025·3 cites·14 claims
- 0390US2026042856A1Antibodies to cd70argenx BV·Filed 2025·Application pending·0 cites
- 0488US12240875B2Use of FCRN antagonists for treatment of generalized myasthenia gravisargenx BV·Filed 2018·Granted Mar 4, 2025·3 cites·21 claims
- 0588US11591388B2Pharmaceutical formulations of FcRn inhibitors suitable for subcutaneous administrationargenx BV·Filed 2020·Granted Feb 28, 2023·6 cites·21 claims
- 0685US12202900B2Compositions and methods for treating immune thrombocytopeniaargenx BV·Filed 2019·Granted Jan 21, 2025·4 cites·14 claims
- 0785US11712468B2CD70 combination therapyargenx BV·Filed 2019·Granted Aug 1, 2023·3 cites·36 claims
- 0883US11434298B2Antibodies to CD70argenx BV·Filed 2019·Granted Sep 6, 2022·1 cites·11 claims
- 0981US2024002484A1ANTIBODIES TO HUMAN COMPLEMENT FACTOR C2b AND METHODS OF USEargenx BV·Filed 2023·Application pending·0 cites
- 1081US2024158492A1Il-6 binding moleculesargenx BV·Filed 2023·Application pending·0 cites
- 1181US2023265201A1Antibodies to cd70argenx BV·Filed 2022·Application pending·0 cites
- 1280US12403175B2Methods for treating pemphigus disordersargenx BV·Filed 2021·Granted Sep 2, 2025·1 cites·21 claims
- 1379US11708403B2Antibodies to human complement factor C2B and methods of useargenx BV·Filed 2022·Granted Jul 25, 2023·0 cites·14 claims
- 1478US12565538B2FCRN/antigen-binding molecules and methods of useargenx BV·Filed 2025·Granted Mar 3, 2026·0 cites·11 claims
- 1578US11591386B2Antibodies to human complement C2Bargenx BV·Filed 2021·Granted Feb 28, 2023·0 cites·20 claims
- 1676US2025388700A1Variant fc regionsargenx BV·Filed 2025·Application pending·0 cites
- 1776US2025388699A1Variant fc regionsargenx BV·Filed 2025·Application pending·0 cites
- 1875US11827701B2IL-6 binding moleculesargenx BV·Filed 2021·Granted Nov 28, 2023·0 cites·18 claims
- 1975US2024368311A1Bispecific antigen binding constructargenx BV·Filed 2024·Application pending·0 cites
- 2075US2025059262A1Method of preparing ph-dependent antibodiesargenx BV·Filed 2024·Application pending·0 cites
- 2173US2025215090A1Compositions and methods for treating immune thrombocytopeniaargenx BV·Filed 2024·Application pending·0 cites
- 2271US2026015415A1Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administrationargenx BV·Filed 2025·Application pending·0 cites
- 2371US2024026010A1Galectin-10 antibodiesargenx BV·Filed 2023·Application pending·0 cites
- 2471US2024033353A1Cd70 combination therapyargenx BV·Filed 2023·Application pending·0 cites
- 2571US2025382388A1Fcrn/hsa binding molecules and methods of useargenx BV·Filed 2025·Application pending·0 cites
- 2670US11530271B2CD70 combination therapyargenx BV·Filed 2019·Granted Dec 20, 2022·1 cites·24 claims
- 2770US2025122288A1Fcrn binding molecules and methods of useargenx BV·Filed 2024·Application pending·0 cites
- 2870US2022275035A1Fcrn antagonists and methods of useargenx BV·Filed 2022·Application pending·0 cites
- 2969US11447544B2Anti-IL-22R antibodiesargenx BV·Filed 2019·Granted Sep 20, 2022·0 cites·26 claims
- 3068US2024352138A1Combined antagonists against il-5/il-5r and either il-4/il-4r or il-13/il-13rargenx BV·Filed 2024·Application pending·0 cites
- 3168US2025051453A1Methods for treating bullous pemphigoid using fcrn antagonistsargenx BV·Filed 2024·Application pending·0 cites
- 3267US12180293B2CD70 combination therapyargenx BV·Filed 2022·Granted Dec 31, 2024·0 cites·18 claims
- 3367US2023357382A1Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administrationargenx BV·Filed 2023·Application pending·0 cites
- 3464US2026008854A1Methods for vaccination of a subject treated with an fcrn antagonistargenx BV·Filed 2025·Application pending·0 cites
- 3563US11649295B2Asymmetric multispecific antibodiesargenx BV·Filed 2019·Granted May 16, 2023·0 cites·16 claims
- 3663US2024369467A1Methods for treating patients with an autoantibody-mediated diseaseargenx BV·Filed 2024·Application pending·0 cites
- 3761US12071486B2Bispecific antigen binding constructargenx BV·Filed 2018·Granted Aug 27, 2024·0 cites·4 claims
- 3861US2025152707A1Cd70 combination therapyargenx BV·Filed 2025·Application pending·0 cites
- 3961US2024325528A1Subcutaneous unit dosage formsargenx BV·Filed 2024·Application pending·0 cites
- 4060US2025101111A1Fcrn antagonists and methods of useargenx BV·Filed 2024·Application pending·0 cites
- 4160US2025051477A1Anti-musk antibodies for use in treating neuromuscular disordersargenx BV·Filed 2024·Application pending·0 cites
- 4260US2025179133A1Use of fcrn antagonists for treatment of generalized myasthenia gravisargenx BV·Filed 2025·Application pending·0 cites
- 4359US2025188190A1In utero treatment of a fetus having genetic disease/neuromuscular diseaseargenx BV·Filed 2024·Application pending·0 cites
- 4458US2024182590A1Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitorargenx BV·Filed 2023·Application pending·0 cites
- 4558US2025388679A1Subcutaneous fcrn antagonist formulations and methods of use thereofargenx BV·Filed 2025·Application pending·0 cites
- 4658US2024109960A1Anti-il-9 antibodies and methods of use thereofargenx BV·Filed 2023·Application pending·0 cites
- 4757US2025084171A1Methods for treating myositis using fcrn antagonistsargenx BV·Filed 2024·Application pending·0 cites
- 4856US12060413B2Method of preparing pH-dependent antibodiesargenx BV·Filed 2018·Granted Aug 13, 2024·0 cites·33 claims
- 4956US2025059285A1Galectin-10 antibodiesargenx BV·Filed 2024·Application pending·0 cites
- 5055US12030949B2Multispecific antibodies against IL-5 and IL-4Rargenx BV·Filed 2019·Granted Jul 9, 2024·0 cites·20 claims
Showing the top 50 of 57 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →